IRIS
ADAMO, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.546
NA - Nord America 2.499
AS - Asia 1.224
SA - Sud America 447
AF - Africa 32
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 1
Totale 6.753
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.462
RU - Federazione Russa 827
SG - Singapore 564
SE - Svezia 525
IE - Irlanda 444
BR - Brasile 403
CN - Cina 354
DE - Germania 157
HK - Hong Kong 150
UA - Ucraina 150
GB - Regno Unito 91
IT - Italia 89
FI - Finlandia 81
FR - Francia 59
PL - Polonia 44
VN - Vietnam 42
IN - India 38
BE - Belgio 23
AR - Argentina 19
CA - Canada 17
BD - Bangladesh 13
ZA - Sudafrica 13
AT - Austria 11
MX - Messico 11
CZ - Repubblica Ceca 9
MA - Marocco 9
UZ - Uzbekistan 9
CO - Colombia 8
PK - Pakistan 8
ID - Indonesia 7
IQ - Iraq 7
NL - Olanda 7
ES - Italia 6
VE - Venezuela 6
TR - Turchia 5
DZ - Algeria 4
JO - Giordania 4
JP - Giappone 4
PE - Perù 4
AE - Emirati Arabi Uniti 3
EC - Ecuador 3
JM - Giamaica 3
LT - Lituania 3
PT - Portogallo 3
AL - Albania 2
AM - Armenia 2
CH - Svizzera 2
CL - Cile 2
CR - Costa Rica 2
EU - Europa 2
KZ - Kazakistan 2
LB - Libano 2
LK - Sri Lanka 2
LV - Lettonia 2
PA - Panama 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
XK - ???statistics.table.value.countryCode.XK??? 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BO - Bolivia 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EG - Egitto 1
GA - Gabon 1
GR - Grecia 1
GT - Guatemala 1
HU - Ungheria 1
IM - Isola di Man 1
IR - Iran 1
KE - Kenya 1
KG - Kirghizistan 1
KR - Corea 1
MK - Macedonia 1
NG - Nigeria 1
NP - Nepal 1
PS - Palestinian Territory 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
TM - Turkmenistan 1
TN - Tunisia 1
Totale 6.753
Salva come PNG Salva come JPEG
Città #
Dublin 442
Moscow 398
Chandler 333
Jacksonville 291
Nyköping 282
Singapore 271
Ashburn 264
Dallas 257
Beijing 166
Hong Kong 150
Ann Arbor 85
Dearborn 81
Los Angeles 76
New York 70
Cambridge 64
Princeton 64
Medford 61
Des Moines 50
The Dalles 47
Warsaw 41
Boardman 40
São Paulo 40
Lancaster 34
Buffalo 31
Pune 28
Messina 26
Brussels 23
Frankfurt am Main 20
Munich 20
Tianjin 19
Rio de Janeiro 16
Jinan 15
Wilmington 14
Redondo Beach 13
Shenyang 13
Woodbridge 13
Brooklyn 12
Ho Chi Minh City 12
Johannesburg 12
Boston 11
Hanoi 11
Helsinki 11
Nanjing 11
Belo Horizonte 10
Council Bluffs 9
Stockholm 9
Tashkent 9
Vienna 9
London 8
Montreal 8
Chicago 7
Nanchang 7
Ningbo 7
Porto Alegre 7
San Mateo 7
Washington 7
Dong Ket 6
Fortaleza 6
Grammichele 6
Haikou 6
Hebei 6
Manchester 6
Mexico City 6
Olomouc 6
Poplar 6
San Jose 6
Turku 6
Curitiba 5
Goiânia 5
Guangzhou 5
Hangzhou 5
Houston 5
Jakarta 5
Taiyuan 5
Amsterdam 4
Atlanta 4
Barbacena 4
Bogotá 4
Brasília 4
Campinas 4
Casablanca 4
Denver 4
Jiaxing 4
Juiz de Fora 4
Milan 4
Orem 4
Orta di Atella 4
Osasco 4
Roubaix 4
San Francisco 4
São José dos Campos 4
Tokyo 4
Amman 3
Baghdad 3
Bexley 3
Bremen 3
Buenos Aires 3
Catania 3
Caxias do Sul 3
Clearwater 3
Totale 4.239
Salva come PNG Salva come JPEG
Nome #
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 172
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 171
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 160
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 157
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 156
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 150
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 139
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 137
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. 136
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications. 133
Breast. La terapia primaria: stato dell'arte 132
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 131
Hereditary breast/ovarian cancer families: The impact of mutation prediction models on BRCA1/2 mutation screening costs. 130
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 127
Combination of Gemcitabine (GEM and Liposomal Pegylate Doxorubicin (PLD) in recurrent/ metastatic breast carcinoma: a phase II study. 124
BRCA1 missense variants of uncertain clinical significance in unaffected and breast/ovarian cancer of the sicilian population. 121
Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. 115
A Missense Mutation Associated to Early Onset Breast Cancer in A Sicilian Woman. 114
A rare case of malignant solitary fibrous tumor of the spinal cord 113
Embolia polmonare 109
Incidence and preferential localizations of bone metastases: biomolecolar and clinical implications. 108
AlphaB-crystallin (aBC) expression in breast cancer brain metastases (BM) and primary breast cancer (pBC) with eventual BM and association with outcome 108
May the istotype influence the response to pemetrexed in patients with non small cell lung cancer? Preliminary data of our clinical experience. 107
BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models. 107
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 106
BRCA1 germline mutations in sicilian breast and/or ovarian cancer families and their implications for genetic counseling. 106
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile. 104
SAFETY AND ACTIVITY OF ERLOTINIB (TARCEVA) IN HEAVILY PRE-TREATED PATIENTS WITH METASTATIC, REFRACTORY NON SMALL CELL LUNG CANCER 103
Analysis of the expression levels of Leptin gene and it’s receptor in Breast Cancer patients. 101
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 101
Observational study to evaluate the pattern of trastuzumab (T) use and survival outcomes in HER2-positive (HER2+) early breast cancer (EBC): Regional Southern Italy experience. 99
A study of a new germline mutation in BRCA1 gene in two Sicilian families: a founder mutation ? 98
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 98
Q356R and S1512I are BRCA1 variants that may be associated with breast cancer in a Sicilian family. 96
From Adjuvant to Preventive Breast Cancer Treatment: bridging the gap over troubled waters. 95
Infra-centimetric HER2 positive Breast Cancer: The Southern Italy Experience. 95
Preclinical Development of an Intracranial Triple Negative Breast Cancer (TNBC) Tumor Model: A Pilot Study. 92
Phase II trial ZD1839(IRESSA)second-third line in patients with advanced/metastatic non small cell lung cancer (NSCLC):preliminary results 91
Strategia Terapeutica nel Carcinoma Prostatico Ormonorefrattario 90
Safety of the combination Capecitabine plus Bevacizumab in the treatment of heavily treated advanced colorectal cancer patients: Our experience. 89
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. 89
Tumor Characteristics and Adjuvant treatment in Very Young Women 89
Role of MTHFR polymorphisms as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: Preliminary data. 88
Neoplasie della testa collo nell’ anziano 88
Phosphatidylinositol 3-kinase (PI3K) pathway activation in breast cancer brain metastases. 88
Multicenter study in women with infracentimetric HER2 positive breast cancer: The Regional Sicilian experience. 87
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 86
Safety and clinical activity of trastuzumab (TSM) containing therapies in heavily pretreated patients with metastatic breast cancer (MBC): A five-year experience 85
Risk evaluation in breast cancer: a preliminary study of pre-metastatic niche in 252 lymphnodes 85
Ruolo di Trastuzumab nella terapia adiuvante del carcinoma mammario operabile. 84
Safety of Zoledronic acid in bone metastatic breast cancer patients: A retrospective analysis. 84
Simultaneous development and parallel course of disseminated superficial porokeratosis and ovarian cancer: Coincidental association or true paraneoplastic syndrome? 84
Turbe della nutrizione: anoressia e cachessia. 82
Risk evaluation in breast cancer: a preliminary study of pre-metastatic niche in 252 negative lymphnodes. 82
SAFETY OF PEGILATED LIPOSOMAL DOXORUBICIN AND GEMCITABINE IN ELDERLY WOMEN (>65 YEARS)WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER 79
Prognostic significance of elevated pretreatment serum CA-125 in patients (pts) with epithelial ovarian cancer (CEO) treated with surgery and platinum/taxane-based chemotherapy. 79
Stratifying triple-negative breast cancer: which definition(s) to use? 79
Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels 76
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 72
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications 72
Safety and activity of trastuzumab (TRA) containing therapies as treatment of metastatic breast cancer(MBC): a five year experience. 71
Primary Therapy in Breast Cancer: The State of the Art. 71
Safety of trastuzumab-containing therapies in elderly women with metastatic breast cancer. 70
null 52
The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. 47
null 37
null 33
null 22
Totale 6.782
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.050
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.050
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021241 0 0 0 0 0 62 12 38 8 49 41 31
2021/2022470 5 69 7 9 21 3 23 13 8 107 66 139
2022/20231.362 98 146 62 103 96 141 29 84 540 5 43 15
2023/2024350 22 49 19 33 30 136 36 1 7 3 4 10
2024/20251.179 9 21 24 73 60 36 10 220 336 72 133 185
2025/20262.053 154 223 250 198 344 884 0 0 0 0 0 0
Totale 6.782